| Identification | Back Directory | [Name]
JNJ-26070109 | [CAS]
844645-08-5 | [Synonyms]
JNJ-26070109
JNJ-26070109
(JNJ 26070109
Benzamide, 4-bromo-N-[(1R)-1-(2,4-difluorophenyl)ethyl]-2-[(5-quinoxalinylsulfonyl)amino]- | [Molecular Formula]
C23H17BrF2N4O3S | [MOL File]
844645-08-5.mol | [Molecular Weight]
547.37 |
| Hazard Information | Back Directory | [Description]
JNJ-26070109 is cholecystokinin CCK2 receptor antagonist inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat. | [Uses]
JNJ-26070109 is a high-affinity, competitive, orally bioactive, and selective cholecystokinin 2 (CCK2) receptor antagonist with good pharmacokinetic properties, with pKis of 8.49, 7.99, and 7.70 for human, rat, and dog CCK2 receptors, respectively. The dual function of CCK2 receptors in regulating gastric acid secretion and growth of the gastrointestinal mucosa make this an attractive and novel target for the research of gastroesophageal reflux disease[1]. | [IC 50]
CCKBR | [References]
[1] Magda F Morton, et al. JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. J Pharmacol Exp Ther. 2011 J DOI:10.1124/jpet.110.178483 |
|
|